‘Mucocutaneous graft-versus-host disease’ - 19/03/26
, Javier López-Davia, MD a, b, Rafael Botella-Estrada, MD, PhD a, b, cKey words : cutaneous manifestations, emerging therapies, graft-versus-host disease, hematopoietic stem cell transplantation
Abbreviation used : GVHD
Plan
| Funding sources: No specific funding was received from any bodies in the public, commercial, or not-for-profit sectors to carry out the work described in this article. |
|
| Patient consent on file: Consent for the publication of recognizable patient photographs or other identifiable material was obtained by the authors for their use in this publication. |
|
| IRB approval status: Procedures followed here were in accordance with the ethical standards of the standing committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. We have not used patients' names, initials, or assigned hospital numbers. |
Vol 94 - N° 4
P. 1353-1370 - avril 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
